T‐cell‐receptor engagement and tumor ICAM‐1 up‐regulation are required to by‐pass low susceptibility of melanoma cells to autologous CTL‐mediated lysis
- 1 April 1993
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 53 (6) , 994-1001
- https://doi.org/10.1002/ijc.2910530623
Abstract
Tumor-specific and non-specific CD3+, TcRαβ+, CD8+ cytotoxic T-cell (CTL) clones, isolated from tumor-infiltrating lymphocytes (TIL) or peripheral blood lymphocytes (PBL) of a melanoma patient and allogeneic LAK cells, were used to investigate the requirements for bypassing the low lysability of some melanoma clones derived from an S.C. metastasis from which highly lysable clones were also obtained. Cytofluorimetric analysis showed that all melanoma clones expressed ICAM-1, although to different extents, reaching a 10-fold difference in fluorescence units, while HLA class-1 antigens were similarly expressed. The differences in expression of ICAM-1 among tumor clones correlated with differences in lysability, by both specific and non-specific CTL, but were not large enough to affect lymphocyte-tumor conjugate formation. Cytokine- or gene-transfer-mediated up-regulation of ICAM-1 did not induce de novo lysis of ICAM-1low tumor cells; however, it markedly enhanced a low level of killing of the same cells by tumor-specific, TcR-dependent and HLA-restricted CTL clones but not by non-specific, TcR-independent effectors. In addition, lysis of melanoma clones by any effector was similarly inhibited by anti-ICAM-1 and anti-LFA-1 antibodies. This indicates that by-pass of low lysability of ICAM-1low melanoma clones by CTL clones, after ICAM-1 up-regulation, is possible only if simultaneous LFA-1 and TcR engagement takes place. In addition, these results suggest that the constitutive high level of expression of ICAM-1 on the subset of ICAM-1high melanoma cells must be only one of the factors contributing to the high lysability of these cells by any effector.Keywords
This publication has 22 references indexed in Scilit:
- ??1-Integrins on Melanoma Clones Regulate the Interaction with Autologous Cytolytic T-Cell ClonesJournal of Immunotherapy, 1992
- Heterogeneous susceptibility of human melanoma clones to monocyte cytotoxicity: Role of ICAM‐1 defined by antibody blocking and gene transferEuropean Journal of Immunology, 1992
- Two autologous melanoma-specific and MHC-restricted human T cell clones with identical intra-tumour reactivity do not share the same TCR Vα and Vβ gene familiesMelanoma Research, 1991
- Increased susceptibility of ifn-γ-treated neuroblastoma cells to lysis by lymphokine-activated killer cells: Participation of ICAM-1 induction on target cellsInternational Journal of Cancer, 1991
- Human melanoma cells with high susceptibility to cell‐mediated lysis can be identified on the basis of icam‐1 phenotype, vla profile and invasive abilityInternational Journal of Cancer, 1990
- Icam ‐ melanoma cells are relatively resistant to cd3‐mediated t‐cell lysisInternational Journal of Cancer, 1990
- Adhesion receptors of the immune systemNature, 1990
- Cellular Immune Response Against Autologous Human Malignant Melanoma: Are In Vitro Studies Providing a Framework for a More Effective Immunotherapy?JNCI Journal of the National Cancer Institute, 1990
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- PREVENTION OF GRAFT FAILURE BY AN ANTI-HLFA-1 MONOCLONAL ANTIBODY IN HLA-MISMATCHED BONE-MARROW TRANSPLANTATIONThe Lancet, 1986